CervoMed (CRVO) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary

Clinical development and drug mechanism

• Neflamapimod is an oral drug targeting synaptic dysfunction in early and middle stages of neurodegeneration, showing clinical proof of concept in dementia with Lewy bodies (DLB) and progressing to phase III next year.

• The drug acts on neuroinflammation affecting the cholinergic system in the basal forebrain, with robust effects seen in the pure DLB population, distinct from Alzheimer's disease.

• Clinical studies, including phase IIa and IIb, focused on patients without Alzheimer's co-pathology, using blood-based biomarkers to define the population.

• The primary endpoint in trials was the Clinical Dementia Rating Sum of Boxes (CDR-SB), a standard measure for dementia progression and treatment outcomes.

• Neflamapimod demonstrated reversal and improvement in clinical data, with over 300 patients and volunteers evaluated across studies.

Market opportunity and disease context

• DLB is the third most common chronic neurodegenerative disease, with 175,000 patients in the U.S., representing a multi-billion dollar market opportunity.

• DLB impacts attention, executive function, and motor skills, progressing more rapidly than Alzheimer's and significantly affecting quality of life.

• No approved therapies currently target the underlying disease in DLB, making it a major untapped opportunity.

• The market is comparable in size and specialty focus to multiple sclerosis, with similar salesforce and pricing models.

• Annual per patient pricing is expected in the $40,000–$50,000 range, potentially higher, reflecting high unmet need and specialty care.

Clinical trial results and regulatory pathway

• The phase IIb RewinD-LB study showed a 52% reduction in clinical worsening on the CDR-SB over 16 weeks, rising to 67% in a more precisely defined population.

• Clinically meaningful effects were also observed on global impression of change, with a p-value of 0.033, supporting impact on disease progression.

• The study compared low and high dose capsules, confirming manufacturing and stability requirements for commercial scale.

• Regulatory discussions with the FDA are ongoing, with expectations for a single 24-week phase III trial using CDR-SB as the primary endpoint.

• The company is aligning on biomarker cutoffs and expects no major regulatory hurdles, given the high unmet need and positive trial data.